Because Foretinib is a VEGFR2 inhibitor, its anti-angiogenic effect is expected and two previous studies clearly demonstrated the suppression of tumor angiogenesis in melanoma and pancreatic islet cancer animal models by this inhibitor [4, 10]. Here, KDR is linked to exocrine pancreatic carcinoma.